Patil Nikita, Kalgotra Pankush, Sundaram Suneha, Melquist Stephanie, Parasa Sravanthi, Desai Madhav, Sharma Prateek
Hospitalist Department, Cape Fear Valley Medical Center, Fayetteville, North Carolina.
Department of Systems and Technology, Harbert College of Business, Auburn University, Auburn, Alabama.
Gastro Hep Adv. 2023;2(1):37-45. doi: 10.1016/j.gastha.2022.08.004. Epub 2022 Aug 26.
Gastrointestinal (GI) symptoms are present in 20% of patients with SARS-CoV-2 coronavirus infection (COVID-19). We studied the association of GI symptoms (in patients with COVID-19) with adverse outcomes and factors associated with poor outcomes in these patients.
The study cohort included 100,902 patients from the Cerner Real-World Data COVID-19 Database of hospital encounters and emergency department visits with COVID-19 infection from December 1, 2019, to November 30, 2020. Multivariate analysis was used to study the effect of GI symptoms on adverse outcomes and the factors associated with mortality, acute respiratory distress syndrome (ARDS), sepsis, and ventilator requirement or oxygen dependence in patients with COVID-19 and GI symptoms.
Patients with COVID-19 and GI symptoms were significantly more likely to have ARDS (odds ratio [OR] 1.20, 95% confidence interval [CI] 1.11, 1.29), sepsis (OR 1.19, 95% CI 1.14, 1.24), acute kidney injury (OR 1.30, 95% CI 1.24, 1.36), venous thromboembolism (OR 1.36, 95% CI 1.22, 1.52), or GI bleed (OR 1.62, 95% CI 1.47, 1.79) and less likely to experience cardiomyopathy (OR 0.87, 95% CI 0.77, 0.99) or death (OR 0.71, 95% CI 0.67, 0.75). Among those with GI symptoms, older age, higher Charlson comorbidity index scores, and use of proton pump inhibitors/H2 receptor antagonists were associated with higher mortality, ARDS, sepsis, and ventilator or oxygen requirement.
Patients with COVID-19 who have GI symptoms have overall worse in-hospital complications but less cardiomyopathy and mortality. Older age, higher comorbidity scores, and the use of proton pump inhibitors and H2 receptor antagonists are associated with poor outcomes in these patients.
20%的新型冠状病毒感染(COVID-19)患者存在胃肠道(GI)症状。我们研究了(COVID-19患者中的)胃肠道症状与不良结局的关联以及这些患者不良结局的相关因素。
研究队列包括来自Cerner真实世界数据COVID-19数据库的100902例患者,这些患者在2019年12月1日至2020年11月30日期间因COVID-19感染而住院或前往急诊科就诊。采用多变量分析研究胃肠道症状对COVID-19合并胃肠道症状患者不良结局的影响以及与死亡率、急性呼吸窘迫综合征(ARDS)、脓毒症、呼吸机需求或氧依赖相关的因素。
COVID-19合并胃肠道症状的患者发生ARDS(比值比[OR]1.20,95%置信区间[CI]1.11,1.29)、脓毒症(OR 1.19,95%CI 1.14,1.24)、急性肾损伤(OR 1.30,95%CI 1.24,1.36)、静脉血栓栓塞(OR 1.36,95%CI 1.22,1.52)或胃肠道出血(OR 1.62,95%CI 1.47,1.79)的可能性显著更高,而发生心肌病(OR 0.87,95%CI 0.77,0.99)或死亡(OR 0.71,95%CI 0.67,0.75)的可能性更低。在有胃肠道症状的患者中,年龄较大、Charlson合并症指数评分较高以及使用质子泵抑制剂/H2受体拮抗剂与较高的死亡率、ARDS、脓毒症以及呼吸机或氧需求相关。
有胃肠道症状的COVID-19患者总体住院并发症更严重,但心肌病和死亡率较低。年龄较大、合并症评分较高以及使用质子泵抑制剂和H2受体拮抗剂与这些患者的不良结局相关。